BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 29978365)

  • 1. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
    Park TS; Thomas SM; Rosenberger LH; Fayanju OM; Plichta JK; Blitzblau RC; Ong CT; Hyslop T; Hwang ES; Greenup RA
    Ann Surg Oncol; 2018 Oct; 25(10):3019-3029. PubMed ID: 29978365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
    Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
    Corona SP; Bortul M; Scomersi S; Bigal C; Bottin C; Zanconati F; Fox SB; Giudici F; Generali D
    Breast Cancer Res Treat; 2020 Apr; 180(3):735-745. PubMed ID: 32060782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
    Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
    Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
    Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
    Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
    Cohen BL; Collier AL; Kelly KN; Goel N; Kesmodel SB; Yakoub D; Moller M; Avisar E; Franceschi D; Macedo FI
    Ann Surg Oncol; 2020 Jun; 27(6):1830-1841. PubMed ID: 31989360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
    Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
    Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
    Kantor O; Sipsy LM; Yao K; James TA
    Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is axillary lymph node dissection necessary for positive preoperative aspiration cytology lymph node results?
    Horváth Z; Paszt A; Simonka Z; Látos M; Kaizer L; Hamar S; Vörös A; Ormándi K; Fejes Z; Lázár G
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):504-510. PubMed ID: 31708307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.
    Hessler LK; Molitoris JK; Rosenblatt PY; Bellavance EC; Nichols EM; Tkaczuk KHR; Feigenberg SJ; Bentzen SM; Kesmodel SB
    Ann Surg Oncol; 2017 Oct; 24(10):2907-2914. PubMed ID: 28766198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation.
    Cox K; Weeks J; Mills P; Chalmers R; Devalia H; Fish D; Sever A
    Ann Surg Oncol; 2016 Jan; 23(1):58-64. PubMed ID: 25990967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.